Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.

Autor: Huxley S; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Moriarty J; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Hlatky MA; Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Lennon R; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Bailey K; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Bell M; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Geller N; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Lerman A; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Mathew V; Worldwide Network of Innovation In Clinical Education and Research (WNICER) Institute, New York, NY, USA., Rosenberg Y; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Farkouh M; Peter Munk Cardiac Centre, Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON, Canada., Rihal C; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Borah B; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. borah.bijan@mayo.edu., Pereira NL; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. pereira.naveen@mayo.edu.
Jazyk: angličtina
Zdroj: The pharmacogenomics journal [Pharmacogenomics J] 2024 Oct 08; Vol. 24 (6), pp. 32. Date of Electronic Publication: 2024 Oct 08.
DOI: 10.1038/s41397-024-00353-y
Abstrakt: CYP2C19 loss of function (LOF) carriers undergoing percutaneous coronary intervention (PCI) have an increased risk of ischemic events when treated with clopidogrel. PCI patients in TAILOR-PCI were randomized to clopidogrel or genotype-guided (GG) therapy in which LOF carriers received ticagrelor and non-carriers clopidogrel. Direct medical costs associated with a GG approach have not been described before. TAILOR-PCI participants for whom direct medical costs were available for the duration from the date of PCI to one-year post PCI were included. Primary cost estimates were obtained from the Mayo Clinic Cost Data Warehouse. There were no differences in direct medical costs between the GG and clopidogrel groups (mean $20,682 versus $19,747, p = 0.11) however total costs were greater in the GG group (mean $21,245 versus $19,891, p = 0.02) which was primarily driven by ticagrelor costs. In conclusion the increased expense of a GG strategy post PCI as compared to clopidogrel for all is primarily driven by the cost of ticagrelor.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: